

EXHIBIT 2

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

HOSPIRA, INC.)	
)	
Plaintiff,)	C.A. Nos. 1:16-cv-00651
)	1:17-cv-07903
v.)	
)	Hon. Rebecca R. Pallmeyer
FRESENIUS KABI USA, LLC)	
)	
Defendant.)	

CONSENT JUDGMENT AND STIPULATED DISMISSAL

WHEREAS, Plaintiff Hospira, Inc. (“Hospira”) filed Complaints against Defendant Fresenius Kabi USA, LLC (“Fresenius Kabi”), captioned *Hospira, Inc. v. Fresenius Kabi USA, LLC*, 16-cv-651 and 17-cv-7903 for alleged infringement of U.S. Patent Nos. 8,242,158 (“the ’158 patent”); 8,338,470 (“the ’470 patent”); 8,455,527 (“the ’527 patent”); U.S. Patent No. 8,648,106 (“the ’106 patent”); U.S. Patent No. 9,320,712 (“the ’712 patent”); and U.S. Patent No. 9,616,049 (“the ’049 patent”) (collectively “the asserted patents”), related to Fresenius Kabi’s September 30, 2015 submission of Abbreviated New Drug Application No. 208129 and all amendments and supplements thereto (“ANDA No. 208129”) seeking approval to market dexmedetomidine hydrochloride products;

WHEREAS, Fresenius Kabi filed Counterclaims alleging that the asserted patents are invalid and/or will not be infringed by the manufacture, use, sale, offering for sale, or importation of dexmedetomidine hydrochloride products described in ANDA No. 208129 (“Fresenius Kabi ANDA Products”);

WHEREAS, Hospira and Fresenius Kabi stipulated to the narrowing of asserted claims by way of stipulation entered on January 29, 2018. D.I. 93 in Case No. 16 C 651;

WHEREAS, Hospira informed Fresenius Kabi as of June 17, 2018 that it would further narrow the asserted claims that it would continue to assert;

WHEREAS, in *Hospira, Inc. v. Amneal Pharmaceuticals LLC*, Civ. Action No. 1:15-cv-00697-RGA (D. Del.), the court entered judgment finding, *inter alia*, that claims 3 and 4 of the '158 patent, claim 4 of the '470 patent, and claim 5 of the '527 patent are invalid. D.I. 121;

WHEREAS, Hospira will not appeal that court's judgment with respect to the '158, '470, and '527 patents;

WHEREAS, Fresenius Kabi received Tentative Approval on March 26, 2018 with regard to ANDA No. 208129;

IT IS HEREBY ORDERED AND ADJUDGED:

That claims 3 and 4 of the '158 patent are invalid, that Hospira did not assert any of the remaining claims of the '158 patent against the Fresenius Kabi ANDA Products, and that patent is dismissed with prejudice;

That claim 4 of the '470 patent is invalid, that Hospira did not assert any of the remaining claims of the '470 patent against the Fresenius Kabi ANDA Products, and that patent is dismissed with prejudice;

That claim 5 of the '527 patent is invalid, that Hospira did not assert any of the remaining claims of the '527 patent against the Fresenius Kabi ANDA Products, and that patent is dismissed with prejudice;

The parties stipulate that the Fresenius Kabi ANDA Products do not infringe claim 5 of the '712 patent, that Hospira did not assert any of the remaining claims of the '712 patent against the Fresenius Kabi ANDA Products, and that patent is dismissed with prejudice;

That this judgment shall finally conclude and dispose of all claims related to the '158 Patent, the '470 Patent, the '527 Patent, and the '712 patent as to Fresenius Kabi and Hospira with regard to the Fresenius Kabi ANDA Products. All claims, counterclaims, affirmative defenses, and demands related to these patents are dismissed with prejudice;

That this judgment is a final adjudication on the merits with respect to all claims related to the '158 Patent, the '470 Patent, the '527 Patent, and the '712 Patent as to Fresenius Kabi and Hospira with respect to the Fresenius Kabi ANDA Products; and

That this judgment constitutes a final, non-appealable judgment.

ENTER:



Dated: December 21, 2018

REBECCA R. PALLMEYER
United States District Judge

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF ILLINOIS
EASTERN DIVISION**

HOSPIRA, INC.)	
)	
Plaintiff,)	C.A. Nos. 1:16-cv-00651
)	1:17-cv-07903
v.)	
)	Hon. Rebecca R. Pallmeyer
FRESENIUS KABI USA, LLC)	
)	
Defendant.)	

CONSENT JUDGMENT AND STIPULATED DISMISSAL

WHEREAS, Plaintiff Hospira, Inc. (“Hospira”) filed Complaints against Defendant Fresenius Kabi USA, LLC (“Fresenius Kabi”), captioned *Hospira, Inc. v. Fresenius Kabi USA, LLC*, 16-cv-651 and 17-cv-7903 for alleged infringement of U.S. Patent Nos. 8,242,158 (“the ’158 patent”); 8,338,470 (“the ’470 patent”); 8,455,527 (“the ’527 patent”); U.S. Patent No. 8,648,106 (“the ’106 patent”); U.S. Patent No. 9,320,712 (“the ’712 patent”); and U.S. Patent No. 9,616,049 (“the ’049 patent”) (collectively “the asserted patents”), related to Fresenius Kabi’s September 30, 2015 submission of Abbreviated New Drug Application No. 208129 and all amendments and supplements thereto (“ANDA No. 208129”) seeking approval to market dexmedetomidine hydrochloride products;

WHEREAS, Fresenius Kabi filed Counterclaims alleging that the asserted patents are invalid and/or will not be infringed by the manufacture, use, sale, offering for sale, or importation of dexmedetomidine hydrochloride products described in ANDA No. 208129 (“Fresenius Kabi ANDA Products”);

WHEREAS, Hospira and Fresenius Kabi stipulated to the narrowing of asserted claims by way of stipulation entered on January 29, 2018. D.I. 93 in Case No. 16 C 651;

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.